NNT analysis shows improved clinical and economic outcomes in high-risk CLL with zanubrutinib, suggesting better value.
The NNT analysis demonstrates that treatment with zanubrutinib versus acalabrutinib is associated with more favorable clinical and economic outcomes in R/R CLL, especially in high-risk CLL patients.
No takes yet. Share an insight, caveat, or question.
Shadman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: